Literature DB >> 15010838

Conventional and array-based comparative genomic hybridization analyses of novel cell lines harboring HPV18 from glassy cell carcinoma of the uterine cervix.

Yasuo Hirai1, Yasutaka Kawamata, Nobuhiro Takeshima, Reiko Furuta, Tomoyuki Kitagawa, Tokuichi Kawaguchi, Katsuhiko Hasumi, Sachiko Sugai, Tetsuo Noda.   

Abstract

We established 2 novel human cell lines (GCCOT-1, GCCRK) from glassy cell carcinoma. Both cell lines showed dual tendencies of glandular and squamous differentiation, and thus possess the characteristics resembling reserve cells, the putative origin of most carcinomas arising from the uterine cervix. HPV type 18 DNA including E6-E7, which is commonly found in cell types other than squamous cell carcinoma of uterine cervix, was detected in both cell lines. We analyzed gene copy number alterations of the 2 cell lines using conventional comparative genomic hybridization (CGH) coupled with array-based CGH. Among the putative oncogenes demonstrating copy number gain in both cell lines, FGR(SRC2) at 1p36.2-1 and LAMC2 at 1q25-31 have not been reported to show amplification in previous analyses of conventional cervical cell lines. These oncogenes are thus speculated to be directly associated with oncogenesis of glassy cell carcinoma. On the other hand, among the putative suppressor genes demonstrating copy number loss in both cell lines, the 9q region, ATM at 11q22.3, and CYLD at 16q12-13 have not been reported to show loss in conventional cervical cancer cell lines. These sites are speculated to be important as tumor suppressors directly associated with oncogenesis of glassy cell carcinoma. This study suggests for the first time that together with the presence of HPV type 18, alterations at the above sites are closely associated with oncogenesis of glassy cell carcinoma, a special type of carcinoma in the uterine cervix.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010838

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  17 in total

Review 1.  Deubiquitinating enzymes as novel anticancer targets.

Authors:  Benjamin Nicholson; Jeffrey G Marblestone; Tauseef R Butt; Michael R Mattern
Journal:  Future Oncol       Date:  2007-04       Impact factor: 3.404

Review 2.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

3.  Copy number variation of ubiquitin- specific proteases genes in blood leukocytes and colorectal cancer.

Authors:  Tian Tian; Haoran Bi; Yupeng Liu; Guangxiao Li; Yiwei Zhang; Liming Cao; Fulan Hu; Yashuang Zhao; Huiping Yuan
Journal:  Cancer Biol Ther       Date:  2020-05-04       Impact factor: 4.742

4.  Cylindromatosis Tumor Suppressor Protein (CYLD) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor.

Authors:  Virginia Sanchez-Quiles; Vyacheslav Akimov; Nerea Osinalde; Chiara Francavilla; Michele Puglia; Inigo Barrio-Hernandez; Irina Kratchmarova; Jesper V Olsen; Blagoy Blagoev
Journal:  Mol Cell Proteomics       Date:  2017-06-01       Impact factor: 5.911

5.  CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.

Authors:  Paula Miliani de Marval; Shazia Lutfeali; Jane Y Jin; Benjamin Leshin; M Angelica Selim; Jennifer Y Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-08

6.  A case of Brooke-Spiegler syndrome with a novel mutation in the CYLD gene in a patient with aggressive non-Hodgkin's lymphoma.

Authors:  F Hunstig; S Schulz; I Nieten; U Froster; C Boltze; S Schliemann; A Hochhaus; P La Rosée
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-11       Impact factor: 4.553

7.  Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation.

Authors:  Eirini Trompouki; Ageliki Tsagaratou; Stylianos K Kosmidis; Pascal Dollé; Jun Qian; Dimitris L Kontoyiannis; Wellington V Cardoso; George Mosialos
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

Review 8.  Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.

Authors:  Patrick W Blake; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-07       Impact factor: 4.878

9.  CYLD downregulation is correlated with tumor development in patients with hepatocellular carcinoma.

Authors:  Hiroki Kinoshita; Hirohisa Okabe; Toru Beppu; Akira Chikamoto; Hiromitsu Hayashi; Katsunori Imai; Kosuke Mima; Shigeki Nakagawa; Naomi Yokoyama; Takatoshi Ishiko; Satoru Shinriki; Hirofumi Jono; Yukio Ando; Hideo Baba
Journal:  Mol Clin Oncol       Date:  2013-01-14

10.  CYLD inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways.

Authors:  Hengning Ke; Christina K Augustine; Vineela D Gandham; Jane Y Jin; Douglas S Tyler; Steven K Akiyama; Russell P Hall; Jennifer Y Zhang
Journal:  J Invest Dermatol       Date:  2012-07-26       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.